Close
A recent study investigated a novel vaccine treatment, IFx-Hu2.0, for squamous cell and Merkel cell carcinomas, offering hope for patients with limited treatment options. The vaccine showed a promising 56% response rate to subsequent immunotherapy treatment in patients with Merkel cell carcinoma, indicating its potential to prime the immune system for better responses.
The study focused on patients who had failed standard-of-care immunotherapy, evaluating the safety and efficacy of IFx-Hu2.0. Results showed that the vaccine was well-tolerated and could be safely administered multiple times, with early signs of inducing immune responses in tumors. Further research is needed to explore the full potential of IFx-Hu2.0 in treating these difficult-to-treat cancers.
Evening Standard 7month
Phys.org on MSN.com 13month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
